Acute Kidney Injury Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Acute Kidney Injury Overview

Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in the blood and makes it hard for the kidneys to keep the right balance of fluid in the person’s body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults.

“Acute Kidney Injury Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market. 

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Acute Kidney Injury Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years. Acute Kidney Injury Key players in the market such as – Bessor Pharma, XORTX Therapeutics, RegeneRx Biopharmaceuticals, Sentien Biotechnologies, Pharming Group, Guard Therapeutics, Angion Biomedical, AM Pharma Holding, and others, are developing therapies for the Acute Kidney Injury treatment 

• Acute Kidney Injury Emerging therapies such as – BP 1002, Oxipurinol, Timbetasin, SBI 101, Conestat alfa, RMC 035, ANG-3777, Human recombinant alkaline phosphatase, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.   
• In November 2020, AM-Pharma initiated a trial titled “A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with SA-AKI”
• In September 2021, AM-Pharma and Kyowa Kirin signed Exclusive License Agreement for commercialization of Ilofotase Alfa in Japan 

Acute Kidney Injury Pipeline Therapeutics Assessment

• Acute Kidney Injury Assessment by Product Type
• Acute Kidney Injury By Stage and Product Type
• Acute Kidney Injury Assessment by Route of Administration
• Acute Kidney Injury By Stage and Route of Administration
• Acute Kidney Injury Assessment by Molecule Type
• Acute Kidney Injury by Stage and Molecule Type 

DelveInsight’s Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:

• BP 1002: Bessor Pharma
• Oxipurinol: XORTX Therapeutics
• Timbetasin: RegeneRx Biopharmaceuticals
• SBI 101: Sentien Biotechnologies
• Conestat alfa: Pharming Group
• RMC 035: Guard Therapeutics
• ANG-3777: Angion Biomedical
• Human recombinant alkaline phosphatase: AM Pharma Holding 

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Assessment- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

Acute Kidney Injury Pipeline Analysis:

The Acute Kidney Injury pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Acute Kidney Injury treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
• Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies

Acute Kidney Injury Pipeline Market Drivers

• Increasing prevalence of Acute Kidney Injury
• Growing awareness regarding the early prognosis of the injury

Acute Kidney Injury Pipeline Market Barriers

• Lack of effective therapeutic interventions for prevention or treatment of Acute Kidney Injury
• High cost associated with the Acute Kidney Injury treatment

Scope of Acute Kidney Injury Pipeline Drug Insight    

• Coverage: Global
• Key Acute Kidney Injury Companies: Bessor Pharma, XORTX Therapeutics, RegeneRx Biopharmaceuticals, Sentien Biotechnologies, Pharming Group, Guard Therapeutics, Angion Biomedical, AM Pharma Holding, and others
• Key Acute Kidney Injury Therapies: BP 1002, Oxipurinol, Timbetasin, SBI 101, Conestat alfa, RMC 035, ANG-3777, Human recombinant alkaline phosphatase, and others
• Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
• Acute Kidney Injury Market Dynamics:  Acute Kidney Injury market drivers and Acute Kidney Injury market barriers 

Request for Sample PDF Report for Acute Kidney Injury Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com